Unknown

Dataset Information

0

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.


ABSTRACT: B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is considered the most promising and effective therapy to overcome chemorefractory B-cell NHL. Based on the promising results obtained from pivotal trials, the US Food and Drug Administration and European Medicines Agency approved anti-CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma. Nonetheless, there remain several controversial issues and problems awaiting solutions, including optimal management of toxicities, overcoming relapsed/refractory disease after CAR T-cell therapy, and improving CAR-T manufacturing platform. Definite unmet medical needs among patients with chemorefractory B-cell NHL still exist. CAR T-cell therapy might be a game changer that can defeat chemorefractory B-cell NHL, and further clinical development is warranted. In this review, we summarize the recent clinical developments, clinical implications, and perspectives of CAR T-cell therapy, focusing on B-cell NHL.

SUBMITTER: Makita S 

PROVIDER: S-EPMC6385623 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.

Makita Shinichi S   Imaizumi Katsuaki K   Kurosawa Saiko S   Tobinai Kensei K  

Drugs in context 20190213


B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is considered the most promising and effective therapy to overcome chemorefractory B-cell NHL. Based on the promising results obtained from pivotal trials, the US Food and Drug Administration and European Medicines Agency approved anti-CD19 CAR T-ce  ...[more]

Similar Datasets

| S-EPMC5990429 | biostudies-literature
| S-EPMC7544150 | biostudies-literature
| S-EPMC8278776 | biostudies-literature
| S-EPMC9325766 | biostudies-literature
| S-EPMC5480083 | biostudies-literature
| S-EPMC8972219 | biostudies-literature
| S-EPMC6511294 | biostudies-literature
| S-EPMC5685771 | biostudies-literature
| S-EPMC7475559 | biostudies-literature